All In Biotech

Drug Trial Radar · NCT07326540

Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

A Phase 3 Prospective, Randomized, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of BV100 Plus Low-dose Polymyxin B Compared With Colistin Plus High-dose Ampicillin/Sulbactam in the Treatment of Adult Patients With Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Caused by Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 248 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

248

Planned (sponsor's estimate)

Start

Mar 27, 2026

Primary completion

Dec 30, 2027

Study completion Mar 30, 2028

Sponsor

Lead sponsor
BioVersys SASIndustry
Sponsor type
Industry
Collaborators
BioVersys AG
First posted
Jan 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 82 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part study, with Part A being the randomized, controlled portion of the study in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) suspected or confirmed to be due to carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC). Part B is the single-group portion of the study and includes patients with HABP or VABP with CRABC infections that are resistant to or have failed colistin/polymyxin B treatment.

Conditions

  • Hospital Acquired Bacterial Pneumonia (HABP)
  • Ventilator Associated Bacterial Pneumonia (VABP)
  • Colistin Resistanrt ABC
  • Acinetobacter Baumannii-calcoaceticus Complex

Interventions

  • BV100 (300 mg)Drug

    300 mg BV100 nfused over 2 hours every 12 hours (q12h).Treatment for 7 days up to 14 days if clinically indicated.

  • Polymyxin BDrug

    50 mg polymyxin B infused over 2 hours every 12 hours (q12h).Treatment for 7 days up to 14 days if clinically indicated.

  • ColistinDrug

    Colistin (4,500,000 units infused over 1 hour every 12 hours (q12h), after an initial loading dose of 9,000,000 units infused over 1 hour).Treatment for 7 days up to 14 days if clinically indicated.

  • Ampicillin-SulbactamDrug

    High dose ampicillin/sulbactam (6 g/3 g IV over 4 hours q8h).Treatment for 7 days up to 14 days if clinically indicated.

  • MEROPENEM 2 grams TIDDrug

    meropenem infused over 1 hour every 8 hours (q8h).Treatment for 7 days up to 14 days if clinically indicated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients with All-Cause Mortality in CRABC m-MITT PopulationTime frame: Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital

    Tbilisi, Georgia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.